Neratinib: the emergence of a new player in the management of HER2+breast cancer brain metastasis

被引：19

作者：

Nasrazadani, Azadeh ^{[1
]}

Brufsky, Adam ^{[2
]}

机构：

[1] Univ Pittsburgh, UPMC Hillman Canc Ctr, 5115 Ctr Ave, Pittsburgh, PA 15232 USA

[2] Magee Womens Hosp, UPMC Hillman Canc Ctr, Suite 4628,300 Halket St, Pittsburgh, PA 15213 USA

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 07期

关键词：

breast; metastasis; molecular oncology; novel therapy; NERVOUS-SYSTEM METASTASES; LAPATINIB PLUS CAPECITABINE; TYROSINE KINASE INHIBITOR; 2-POSITIVE BREAST-CANCER; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; CNS METASTASES; TBCRC; 022; TRASTUZUMAB; CHEMOTHERAPY;

D O I：

10.2217/fon-2019-0719

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER2-positive (HER2+) breast cancer has become an effectively treatable disease in the era of targeted therapies, and outcomes have improved such that prognosis of this subtype is demonstrated to be superior to HER2-negative disease. Despite these advances, durable responses in HER2+ metastatic disease are challenged by the increased risk for brain metastasis. Neratinib is an irreversible pan-HER kinase inhibitor that has emerged as an effective agent when combined with capecitabine for the management of HER2+ metastatic breast cancer patients with brain metastasis. The randomized, Phase III, NALA trial compares neratinib plus capecitabine to a currently prevailing regimen of lapatinib plus capecitabine and is provided herein. Analysis of NALA portends meaningful changes on the horizon for the management of HER2+ metastatic breast cancer.

引用

页码：247 / 254

页数：8

共 58 条

[1]

[Anonymous], 2019, J CLIN ONCOL S

[2] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[3] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[4] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].

Bendell, JC ;

Domchek, SM ;

Burstein, HJ ;

Harris, L ;

Younger, J ;

Kuter, I ;

Bunnell, C ;

Rue, M ;

Gelman, R ;

Winer, E .

CANCER, 2003, 97 (12) :2972-2977

[5] Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases [J].

Bernatz, Simon ;

Ilina, Elena I. ;

Devraj, Kavi ;

Harter, Patrick N. ;

Mueller, Klaus ;

Kleber, Sascha ;

Braun, Yannick ;

Penski, Cornelia ;

Renner, Christoph ;

Halder, Rashi ;

Jennewein, Lukas ;

Solbach, Christine ;

Thorsen, Frits ;

Pestalozzi, Bernhard C. ;

Mischo, Axel ;

Mittelbronn, Michel .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)

[6]

BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO

[7]

2-P

[8] Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial [J].

Borges, Virginia F. ;

Ferrario, Cristiano ;

Aucoin, Nathalie ;

Falkson, Carla ;

Khan, Qamar ;

Krop, Ian ;

Welch, Stephen ;

Conlin, Alison ;

Chaves, Jorge ;

Bedard, Philippe L. ;

Chamberlain, Marc ;

Gray, Todd ;

Vo, Alex ;

Hamilton, Erika .

JAMA ONCOLOGY, 2018, 4 (09) :1214-1220

[9] Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER [J].

Brufsky, Adam M. ;

Mayer, Musa ;

Rugo, Hope S. ;

Kaufman, Peter A. ;

Tan-Chiu, Elizabeth ;

Tripathy, Debu ;

Tudor, Iulia Cristina ;

Wang, Lisa I. ;

Brammer, Melissa G. ;

Shing, Mona ;

Yood, Marianne Ulcickas ;

Yardley, Denise A. .

CLINICAL CANCER RESEARCH, 2011, 17 (14) :4834-4843

[10] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

← 1 2 3 4 5 6 →